$11.30
1.62% day before yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Stock price

$11.30
-2.69 19.23% 1M
+4.14 57.82% 6M
+3.20 39.51% YTD
+3.07 37.30% 1Y
+8.45 296.49% 3Y
+5.92 110.04% 5Y
+0.50 4.63% 10Y
-3.70 24.67% 20Y
Nasdaq, Closing price Fri, Sep 26 2025
+0.18 1.62%
ISIN
US21900C3088
Symbol
CRMD
Industry

Key metrics

Basic
Market capitalization
$882.1m
Enterprise Value
$691.4m
Net debt
positive
Cash
$190.7m
Shares outstanding
74.6m
Valuation (TTM | estimate)
P/E
15.9 | 7.0
P/S
7.3 | 3.7
EV/Sales
5.7 | 2.9
EV/FCF
22.7
P/B
4.0
Financial Health
Equity Ratio
71.2%
Return on Equity
-21.2%
ROCE
22.3%
ROIC
87.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$121.5m | $237.6m
EBITDA
$49.9m | $142.2m
EBIT
$49.3m | $128.5m
Net Income
$51.2m | $120.8m
Free Cash Flow
$30.4m
Growth (TTM | estimate)
Revenue
14,897.5% | 446.5%
EBITDA
185.9% | 745.1%
EBIT
184.8% | 674.8%
Net Income
196.3% | 773.8%
Free Cash Flow
159.4%
Margin (TTM | estimate)
Gross
95.6%
EBITDA
41.0% | 59.9%
EBIT
40.6%
Net
42.1% | 50.9%
Free Cash Flow
25.0%
More
EPS
$0.7
FCF per Share
$0.4
Short interest
22.6%
Employees
65
Rev per Employee
$670.0k
Show more

Is CorMedix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

CorMedix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a CorMedix Inc forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a CorMedix Inc forecast:

Buy
85%
Hold
15%

Financial data from CorMedix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
121 121
14,898% 14,898%
100%
- Direct Costs 5.32 5.32
300% 300%
4%
116 116
22,438% 22,438%
96%
- Selling and Administrative Expenses 59 59
15% 15%
48%
- Research and Development Expense 8.09 8.09
26% 26%
7%
50 50
186% 186%
41%
- Depreciation and Amortization 0.54 0.54
286% 286%
0%
EBIT (Operating Income) EBIT 49 49
185% 185%
41%
Net Profit 51 51
196% 196%
42%

In millions USD.

Don't miss a Thing! We will send you all news about CorMedix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CorMedix Inc Stock News

Positive
Seeking Alpha
6 days ago
CorMedix is commercializing DefenCath, the only FDA-approved antimicrobial catheter-lock solution, with strong clinical results and rapid adoption in dialysis clinics. Medicare's TDAPA policy ensures full reimbursement for outpatient treatments, supporting near-term revenue as clinic penetration expands and inpatient rollout begins. Q2 2025 financials show $39.7M net revenue and $19.8M net inco...
Neutral
Seeking Alpha
18 days ago
CorMedix Inc. (NASDAQ:CRMD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Joseph Todisco - CEO & Director Conference Call Participants Ross Cohen Presentation Ross Cohen Okay. So thank you all for joining.
Neutral
PRNewsWire
20 days ago
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The com...
More CorMedix Inc News

Company Profile

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Head office United States
CEO Joseph Todisco
Employees 65
Founded 2006
Website cormedix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today